CS 3700 Ranked First in Trueness in Latest In-Vitro Study


ATLANTA—Scientific literature has shown intraoral scanners to be highly successful in creating digital impressions for designing short-span restorations and partial prosthesis; however, scanning fully edentulous arches is less studied. Now, a new comprehensive in-vitro study testing the trueness of 12 intraoral scanners when scanning full-arch implant impressions has found the CS 3700 intraoral scanner to offer the truest results when capturing scan bodies in an edentulous arch, giving doctors more confidence that they’re getting the best results when creating digital impressions with the CS 3700.   


The study compared the trueness—or how closely the digital scans matched the actual object—of 12 intraoral scanners when scanning a stone model of an edentulous arch with scan bodies. Two methods were used to assess trueness. Method 1 directly evaluated the quality/accuracy of the scan of each intraoral scanner. Method 2 evaluated the resulting accuracy of each intraoral scanner in early stages of prosthetic CAD modeling.


Carestream Dental’s newest scanner, the CS 3700, was shown to have the best trueness, with a mean error 30.4 mm, when tested by Method 1. The study found the performance differences between the scanners tested to be statistically significant, with CS 3700 outperforming all the other 11 scanners.


“Being able to confidently scan a fully edentulous arch is every scanner manufacturer’s goal,” Ed Shellard, D.M.D., chief dental officer, Carestream Dental, said. “The CS 3700 features advanced acquisition software—CS ScanFlow—that ensures the accuracy of the dataset while making it 20 percent faster than the Carestream Dental CS 3600 intraoral scanner.” 


Taking into consideration the results of both methods, the study ranked the CS 3700’s performance among the intraoral scanners with the highest accuracy, defined as having a mean error of <40 mm with Method 1 analysis and <25mm with Method 2 analysis. Carestream Dental’s CS 3600 intraoral scanner was also included in the study and was also listed among the scanners with the highest accuracy. 


Both scanners are capable of high-speed scanning and include smart features like guide arrows that show users the ideal direction to scan. Users can choose from orthodontic, restorative and implant-borne restorative workflows. They can also capture different bite registrations for fabricating sleep devices. 


To learn more about the CS 3700, the CS 3600 or any of Carestream Dental’s innovative solutions, visit carestreamdental.com.



About Carestream Dental

Carestream Dental is committed to transforming dentistry, simplifying technology and changing lives. In this pursuit, we focus on providing the latest in high-quality scanning technology, the smartest chairside systems, the most intuitive practice management software, incredibly accurate imaging software and the data intelligence that helps continually refine patient outcomes. And we offer these solutions for the full range of dental and oral health professionals. For more information please visit carestreamdental.com.

Continue reading



Ladera Ranch, CA; September 23, 2020  Ditron Dental USA, the US affiliate of Ditron Dental, a subsidiary of Ditron Precision Ltd., will officially commence commercial operations for its dental implant portfolio as of October 1st, 2020.  Ditron Dental USA is able to capitalize on over 50 years of experience by the corporate parent in the manufacture of ultra-precise components for the aerospace, automotive, and medical device Industries.  The company applied its multi-disciplinary philosophy teaming engineers, micro-machining operators, and top-notch clinicians to develop its dental implant portfolio, resulting in products with an astounding sub-micron level of accuracy.  The product portfolio is represented by the flagship ULT™ Ultimate Precision Dental Implant System and the MPI™ Molecular Precision Implant System, both featuring a host of design innovations in addition to the ultra-precise manufacturing.


"Our goal is to launch something exceptional in terms of the product line and business approach into what is an already crowded US dental implant market,”, said Ole Jensen, OMS founder of Ditron Dental USA and Chairman of the Board.  “In addition to what I believe to be the most precise dental implants in the world, we have assembled one of the most prestigious clinical advisory boards to help guide and support our path to growth.  As a forwardlooking organization, we have already made substantive investments in antimicrobial technologies that will further differentiate our implant offering in the years to come,” added Dr. Jensen.


“Commercially, we are building out a national team of seasoned dental implant industry professionals to complement our world-class advisory board”, stated Mike Stevens, Chief Executive Officer of Ditron Dental USA. As Mr. Stevens continued, “while the innovations and precision manufacturing are critical to our success, it is the Ditron team members and clinical advisors who will personify and bring to life what we have to offer by introducing clinicians and their patients to the Ditron experience.  I am pleased to have Brian Bashaw, a 30-year dental implant industry veteran and prior executive with some of the market leaders, to be joining Ditron Dental USA to lead our commercial efforts as Chief Commercial Officer.”


The company’s commercialization efforts are being supported by Cellerant Consulting, a dental incubator and highly specialized consulting firm that focuses exclusively on the dental industry.  Cellerant’s CEO, Dr. Lou Shuman, added “we are pleased to be working with Ditron on their US launch.  Dr. Jensen is such a respected and accomplished Oral & Maxillofacial surgeon, so his involvement instills confidence.  Add to that a very solid product portfolio, a best-in-class group of clinical advisors, and a growing team of industry experts and this company is sure to achieve a high level of success.”


To remain apprised of new developments with Ditron Dental USA and to take advantage of special offers, please register at https://ditrondentalusa.com/register/



About Ditron Dental USA: Ditron Dental USA offers a comprehensive portfolio of dental implants and related prosthetic components with a focus on innovation and ultra-precise manufacturing.  The dental implant portfolio includes the ULTUltimate Precision, MPI™ Molecular Precision, and OPI™ One-Piece Dental Implant Systems.  Established in 2020 and headquartered in Ladera Ranch, CA, Ditron Dental USA is the US affiliate of Ditron Dental, a subsidiary of Ditron Precision LTD which was founded in 1968 and is located in Ashkelon, Israel.  The Ditron culture embodies a relentless focus on precision, quality, and reliability as manifest in its customer relationships across the automotive, aerospace, and medical device segments.  Ditron Dental USA aims to complement an exceptional product portfolio with world-class educators, experienced representatives, and a sensible pricing policy to create lasting customer relationships.  For more information visit ditrondentalusa.com.

Continue reading

Trueness of 12 intraoral scanners in the full-arch implant impression: a comparative in vitro study

BMC Oral Health volume 20, Article number: 263 (2020) Cite this article



The literature has not yet validated the use of intraoral scanners (IOSs) for full-arch (FA) implant impression. Hence, the aim of this in vitro study was to assess and compare the trueness of 12 different IOSs in FA implant impression.


A stone-cast model of a totally edentulous maxilla with 6 implant analogues and scanbodies (SBs) was scanned with a desktop scanner (Freedom UHD®) to capture a reference model (RM), and with 12 IOSs (ITERO ELEMENTS 5D®; PRIMESCAN® and OMNICAM®; CS 3700® and CS 3600®; TRIOS3®; i-500®; EMERALD S® and EMERALD®; VIRTUO VIVO® and DWIO®; RUNEYES QUICKSCAN®). Ten scans were taken using each IOS, and each was compared to the RM, to evaluate trueness. A mesh/mesh method and a nurbs/nurbs method were used to evaluate the overall trueness of the scans; linear and cross distances between the SBs were used to evaluate the local trueness of the scans. The analysis was performed using reverse engineering software (Studio®, Geomagics; Magics®, Materialise). A statistical evaluation was performed.


With the mesh/mesh method, the best results were obtained by CS 3700® (mean error 30.4 μm) followed by ITERO ELEMENTS 5D® (31.4 μm), i-500® (32.2 μm), TRIOS 3® (36.4 μm), CS 3600® (36.5 μm), PRIMESCAN® (38.4 μm), VIRTUO VIVO® (43.8 μm), RUNEYES® (44.4 μm), EMERALD S® (52.9 μm), EMERALD® (76.1 μm), OMNICAM® (79.6 μm) and DWIO® (98.4 μm). With the nurbs/nurbs method, the best results were obtained by ITERO ELEMENTS 5D® (mean error 16.1 μm), followed by PRIMESCAN® (19.3 μm), TRIOS 3® (20.2 μm), i-500® (20.8 μm), CS 3700® (21.9 μm), CS 3600® (24.4 μm), VIRTUO VIVO® (32.0 μm), RUNEYES® (33.9 μm), EMERALD S® (36.8 μm), OMNICAM® (47.0 μm), EMERALD® (51.9 μm) and DWIO® (69.9 μm). Statistically significant differences were found between the IOSs. Linear and cross distances between the SBs (local trueness analysis) confirmed the data that emerged from the overall trueness evaluation.


Different levels of trueness were found among the IOSs evaluated in this study. Further studies are needed to confirm these results.


Continue reading

Introducing Rhondair – New Dental Aerosol Capture System Provides Post-COVID Protection.

Introducing Rhondair – New Dental Aerosol Capture System Provides Post-COVID Protection.

Rhondium Dental Labs is excited to introduce Rhondair – an Aerosol Capture System designed in New Zealand by local dentist turned serial inventor and entrepreneur Dr Simon McDonald.
Dentists are one of the most at-risk occupations for exposure to pathogens, including COVID-19, primarily due to the aerosol-generating nature of most dental procedures and their proximity to patients. The Rhondair is specifically designed for dental industries to reduce the harmful impacts of dental aerosols on both dental practitioners and their patients.

Rhondium was successfully awarded funding from the New Zealand Ministry of Business, Innovation, and Employment’s “COVID-19 Innovation Acceleration Fund”; a government initiative established to accelerate the development of innovative solutions to assist in fighting the global pandemic.
The key philosophy behind the Rhondair is to capture dental aerosols at the source, instead of allowing them to spread and then relying on PPE or disinfecting methods to keep patients and staff safe.
“PPE should be your last line of defence, not your first” says Rhondium Marketing Manager Fin McDonald. “It’s standard risk minimisation. If you have a hazard you can isolate and contain at the source, that’s the best approach.”

The Rhondair’s unique aerodynamic design creates a powerful draw away from a patient to capture created aerosols and incorporates single-use or sterilisable components for ideal infection control. Its enclosed medical-grade H13 HEPA filter captures 99.95% or more of all particles. This includes the size ranges that viruses, COVID-19, and dental aerosols exist within; making it more effective than all common types of medical masks, including N95 variants. The Rhondair can also be kept running when not in active use, such as between patients, to continually purify the air for added protection.
As an essential service, Rhondium Dental Labs has continued to operate throughout the March and August lockdowns in New Zealand, bringing a completely new product through conception, prototyping, development, refinement, production scaling, and to market in little more than 6 months. Rhondium is no stranger to dental research and product development, with previous inventions including the One Visit Crown in 2014 and the McDonald Matrix band in 2018.

Units are now shipping around the world, with high demand across the US and UK. Visit www.rhondium.com for more information.

Continue reading

Botox for TMJ disorders may not lead to bone loss in the short term, but more research is needed

Low-dose botox injections for jaw and facial pain not linked to bone changes, but NYU Dentistry researchers observe reduced bone density at higher doses

New York University

Botox injections to manage jaw and facial pain do not result in clinically significant changes in jaw bone when used short term and in low doses, according to researchers at NYU College of Dentistry. However, they found evidence of bone loss when higher doses were used.

The researchers, whose findings are published in the Journal of Oral Health Rehabilitation, call for further clinical studies to track bone- and muscle-related changes with long-term use of Botox for TMJD, or temporomandibular muscle and joint disorders.

TMJDs are a group of common pain conditions that occur in the jaw joint and surrounding muscles, with the most common type involving the muscles responsible for chewing. While many individuals manage their TMJD symptoms with conservative treatments such as jaw exercises, oral appliances, dietary changes, and pain medication, some do not respond to these treatments.

Botox (or botulinum toxin), an FDA-approved injectable drug known for its wrinkle-reducing capabilities, is approved to treat certain muscle and pain disorders, including migraines. It works in part by temporarily paralyzing or weakening muscles. In the U.S., a Phase 3 clinical trial is currently underway to study the use of Botox to treat TMJD, but in the meantime, it is increasingly being used off-label.

Thus far, small studies using Botox to treat TMJD in humans have had mixed results. In animal studies, Botox injections in jaw muscles have led to major bone loss in the jaw. This is thought to be due to the muscles not being used to exert force needed for bone remodeling, but Botox may also have a direct effect on bone resorption, the process of breaking down bone tissue.

"Given these concerning findings from animal studies, and the limited findings from clinical studies, more research on the safety of Botox for jaw muscles and bones is critically important," said Karen Raphael, professor in the Department of Oral and Maxillofacial Pathology, Radiology and Medicine at NYU College of Dentistry and the study’s lead author.

The NYU study included 79 women with TMJD affecting their facial muscles: 35 of whom received Botox injections (between two and five rounds in the past year) and 44 who were not treated with Botox but may have used other TMJD treatments. Using specialized CT scans, the researchers measured participants’ jaw bone density and volume.

The researchers found that jaw bone density and volume were similar between women who had Botox injections to treat their TMJD and those who did not. While most study participants were given relatively low doses of Botox–smaller than in most clinical trials for TMJD–individuals who received higher doses of Botox were more likely to have lower bone density.

Raphael and her colleagues recommend that more human studies be conducted to better understand the impact of the long-term use of Botox on jaw muscles and bones–and whether it just reduces muscle force on bone or also plays a direct role in altering bone resorption.

"Should Botox receive regulatory approval for the treatment of TMJD, we would recommend that a phase IV study be done using low-radiation CT and MRI to track bone- and muscle-related changes with Botox use, examining both dose and long-term use," said Raphael. "Unless specialized imaging of muscle and bone are conducted among patients who receive Botox treatment over long periods, true cumulative effects will remain unknown."


In addition to Raphael, study authors include Malvin Janal, Vivian Santiago, and David Sirois of NYU College of Dentistry, as well as Aditya Tadinada and Alan Lurie of the University of Connecticut School of Dental Medicine. This research was supported in part by the National Institutes of Health’s National Institute of Dental and Craniofacial Research (R01DE024522).

About NYU College of Dentistry

Founded in 1865, New York University College of Dentistry (NYU Dentistry) is the third oldest and the largest dental school in the US, educating nearly 10 percent of the nation’s dentists. NYU Dentistry has a significant global reach with a highly diverse student body. Visit http://dental.nyu.edu for more.


Continue reading

“Effect of local application of simvastatin in bone regeneration of peri-apical defects-a clinico-radiographic study



Journal of Oral Biology and Craniofacial Research



The present study evaluates and compares the effectiveness of Simvastatin (SIM), Hydroxyapatite (HA), and platelet-rich fibrin (PRF) in bone regeneration of periapical defects.

Material& method

Thirty-nine patients were selected and randomized into three groups, Group 1: HA (n = 13), Group 2: PRF (n = 13), Group 3: SIM (n = 13). After completion of RCT and apicoectomy, the grafts were placed locally in the defect and sutured.


At the end of twelve months, postoperative symptoms and radiographic analysis assessed the outcome of the treatment


Intragroup analysis of CBCT- Periapical Index (PAI) scores at 6th and 12th month revealed a significant change in the SIM group (p = 0.018 and 0.001 respectively), compared to PRF (p = 0.026 and 0.001 respectively) and HA (p = 0.053 and 0.039 respectively). Intergroup analysis of change in the level of CBCT-PAI score was highly significant (p = 0.003).

SIM caused a more considerable change in the level of CBCT-PAI score compared to other groups, thereby indicating a faster rate of bone regeneration.

Continue reading